Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donepezil and Memantine in Moderate to Severe Alzheimer's Disease.

Trial Profile

Donepezil and Memantine in Moderate to Severe Alzheimer's Disease.

Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Donepezil (Primary) ; Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms DOMINO-AD
  • Most Recent Events

    • 22 Aug 2013 Accrual to date is 37% according to United Kingdom Clinical Research Network record.
    • 08 Mar 2012 Results published in the New England Journal of Medicine.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top